GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (NAS:BNTC) » Definitions » Pretax Margin %

Benitec Biopharma (Benitec Biopharma) Pretax Margin % : % (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Benitec Biopharma Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Benitec Biopharma's Pre-Tax Income for the three months ended in Mar. 2024 was $-4.28 Mil. Benitec Biopharma's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Benitec Biopharma's pretax margin for the quarter that ended in Mar. 2024 was %.

The historical rank and industry rank for Benitec Biopharma's Pretax Margin % or its related term are showing as below:

BNTC' s Pretax Margin % Range Over the Past 10 Years
Min: -309885.71   Med: -4204.23   Max: 22.59
Current: -309885.71


BNTC's Pretax Margin % is ranked worse than
98.54% of 1028 companies
in the Biotechnology industry
Industry Median: -155.98 vs BNTC: -309885.71

Benitec Biopharma Pretax Margin % Historical Data

The historical data trend for Benitec Biopharma's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Pretax Margin % Chart

Benitec Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.59 -8,529.90 -23,528.81 -24,942.47 -26,082.67

Benitec Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8,142.59 -66,585.71 - - -

Competitive Comparison of Benitec Biopharma's Pretax Margin %

For the Biotechnology subindustry, Benitec Biopharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benitec Biopharma's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's Pretax Margin % falls into.



Benitec Biopharma Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Benitec Biopharma's Pretax Margin for the fiscal year that ended in Jun. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-19.562/0.075
=-26,082.67 %

Benitec Biopharma's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-4.279/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Benitec Biopharma  (NAS:BNTC) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Benitec Biopharma Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Benitec Biopharma (Benitec Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
Executives
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Megan Boston director, officer: Executive Director LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Steven Michael Oliveira 10 percent owner 18 FIELDSTONE COURT, NEW CITY NY 10956
Patrick Soon-shiong 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Edward F Smith director C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104
California Capital Equity, Llc 10 percent owner 10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Peter Francis director LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Jerel A. Banks director, officer: Chief Executive Officer LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000